Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit

Mikhail Dziadzko, MD, PhD

Status: Completed

Conditions: Neuropathic Pain; Post Intensive Care Unit Syndrome; ICU; Pain, Chronic; COVID-19 Pandemic

Treatments: Diagnostic Test: Quantitative Sensory testing; Other: Pain and neuropsychological questionnaires

Study type: Observational

Funder types: Other

Identifiers

NCT04940208

2020-A02929-30

Details and patient eligibility

About

More than six million French were affected by SARS-COV2 epidemic. About 20% of infected peoples were hospitalized, and about 5% were admitted to the intensive care units (ICU) for severe SARS-COV2 acute respiratory distress syndrome (ARDS) management.

A spectrum of neuropsychiatric sequelae, specific for the ICU exposure, was already described, including post-intensive care syndrome and persistent pain.

A growing body of evidence suggests the impact of SARS-COV2 exposure on the occurrence of neurological disorders and chronic pain syndrome development in COVID-19 patients.

Taking together, one can expect a large number of patients discharged from ICU after severe COVID-19 with high prevalence of persistent pain and psychological disorders. To date, no study has evaluated neither the incidence of persistant pains in ICU COVID-19 survivors, nor pain phenotypes.

The knowledge of such data is crucial in order to anticipate the management of such patients by specialized pain team, and to quantify the possible incurred burden of care.

Our study aims to evaluate the incidence of pain, pain localization and severity, associated pain-related psychological disorders, and to perform quantitative sensory testing in severe COVID-19 patients, admitted to the ICU for more than 48 hours and successfully discharged home during the first French pandemic wave.

Enrollment: 143 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adults (>=18 y.o.)
• hospitalized in the ICU for at least 48 hours
• with SARS-Cov2 infection confirmed by Polymerase Chain Reaction (PCR)/serology and/or a suggestive chest Computed Tomography scan
• during the first wave of COVID 19 from March to December 2020 at three investigator sites (2 in Paris and 1 in Lyon)
• discharged alive from the ICU
• at least 6 months after discharge

Exclusion criteria

• patient refusal
• inability to communicate or to have in-person appointment
• death in the period from ICU discharge to the first phone call for interview

Trial design

143 participants in 1 patient group

post COVID-19 ICU survivors

Description:

Patients hospitalized to the ICU in the context of severe COVID-19 and discharged alive during the first French COVID-19 pandemic wave

Treatment:

Diagnostic Test: Quantitative Sensory testing

Other: Pain and neuropsychological questionnaires